Physician profile
Dick M Yip
NPI 1851374631
$10,432.14
in general payments reported to CMS, 2019-2025
23 companies · $756 in 2025
The $756 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,474 · 2020: $408 · 2021: $1,418 · 2022: $1,293 · 2023: $1,072 · 2024: $1,011 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,912.12 | 2019-2025 | Vemlidy, Livdelzi |
| Abbvie INC. | $1,201.95 | 2019-2025 | Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,107.62 | 2019-2025 | Xifaxan, Plenvu |
| Intercept Pharmaceuticals, INC. | $310.10 | 2019-2023 | Ocaliva |
| Celgene Corporation | $299.61 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $282.19 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $232.98 | 2021 | |
| Madrigal Pharmaceuticals | $137.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $127.98 | 2019-2023 | Gattex |
| Qol Medical, LLC | $115.73 | 2021-2023 | Sucraid |
| Corcept Therapeutics | $112.43 | 2023 | Korlym |
| Ironwood Pharmaceuticals, INC | $105.75 | 2019-2024 | Linzess |
| Ardelyx, INC. | $96.65 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $94.41 | 2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $59.47 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $45.89 | 2020-2025 | Talicia |
| Medtronic, INC. | $41.81 | 2023 | Ligasure |
| Pfizer INC. | $38.02 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $32.47 | 2025 | Dupixent |
| Braintree Laboratories, INC. | $29.89 | 2021-2025 | Suflave, Sutab |
| Alfasigma USA, INC. | $19.39 | 2020 | |
| W. L. Gore & Associates, INC. | $14.70 | 2020 | |
| Shionogi INC | $13.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dick Yip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.